Differences of Hepatitis B Serological Tests in Cirrhosis and Hepatocellular Carcinoma Patients
DOI:
https://doi.org/10.24293/ijcpml.v30i1.2059Keywords:
Serological tests, HBsAg, cirrhosis, HCCAbstract
Cirrhosis and hepatocellular carcinoma (HCC) are the most common complications of chronic hepatitis B. Hepatitis B Virus (HBV) reactivation occurs in the inactive phase, characterized by reappearance of HBsAg or negative HBsAg. The prevalence of occult hepatitis B infection in cirrhosis and HCC ranges from 20% to 60%. This study aimed to analyze the differences in hepatitis B serological tests in patients with cirrhosis and HCC for diagnosis of acute or chronic hepatitis B. The current research was analytical and descriptive with a cross-sectional study design. This study involved 177 patients, including 50 cirrhosis patients and 127 HCC patients. Hepatitis B serological tests (HBsAg, HBeAg, anti-HBe, total anti-HBc) were analyzed using VIDAS instruments by the Enzyme-Linked Fluorescent Immunoassay (ELFA) method. Hepatitis B serological test results were grouped based on the interpretation of serological test results. The data were processed with the statistical test Kolmogorov-Smirnov test, independent T-test, and Chi-Square, and results with p<0.05 were reported as significant. This study found that most males suffer from cirrhosis and HCC due to chronic HBV infection, with a mean age of 57. Chronic hepatitis was most common in patients with cirrhosis and HCC (71.2%). There was no significant difference in the interpretation of the hepatitis B serological test between patients with cirrhosis and HCC, with a p-value of 0.230 (p > 0.05). There was no significant difference in interpreting the hepatitis B serological test between cirrhosis and HCC. Both reactive HBsAg and non-reactive HBsAg can be obtained in cirrhosis and HCC.
Downloads
References
Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia, et al. Clinical practice guidelines of hepatology easy clinical practice guidelines: Management of hepatocellular carcinoma J. Hepatol, 2018; 69: 182–236.
Rybicka M, Bielawski KP. Recent advances in understanding, diagnosing, and treating hepatitis B virus infection. Microorganisms, 2020; 8: 1–29.
Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B virus: Advances in prevention, diagnosis, and therapy. Am. Soc. Microbiol, 2020; 19.
Tsukuda S, Watashi K. Hepatitis B virus biology and life cycle. Antiviral Res, 2020; 182: 104925.
Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia, et al. Clinical practice guidelines of hepatology easy clinical practice guidelines: Management of hepatocellular carcinoma J. Hepatol, 2018; 69: 182–236.
Rybicka M, Bielawski KP. Recent advances in understanding, diagnosing, and treating hepatitis B virus infection. Microorganisms, 2020; 8: 1–29.
Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B virus: Advances in prevention, diagnosis, and therapy. Am. Soc. Microbiol, 2020; 19.
Tsukuda S, Watashi K. Hepatitis B virus biology and life cycle. Antiviral Res, 2020; 182: 104925.
Song JE, Kim DY. Diagnosis of hepatitis B. Ann. Transl. Med, 2016; 4.
Yulia D. Tinjauan pustaka virus hepatitis B ditinjau dari aspek laboratorium. Jurnal Kesehatan Andalas, 2019; 8: 247–254.
Terrault NA, Lok AS, McMahon BJ, Chang KM, Hwang JP, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology, 2018; 67: 1560–1599.
De Almeida Pondé RA. Dynamic profile of the HBeAg-anti-HBe system in acute and chronic hepatitis B virus infection: A clinical-laboratory approach. Mol. Biol. Rep, 2021; 48: 843–854.
Pandyarajan V, Govalan R, Yang JD. Risk factors and biomarkers for chronic hepatitis B associated hepatocellular carcinoma. Int. J. Mol. Sci, 2021; 22: 1–19.
Bozza C, Cinausero M, Iacono D, Puglisi F. Hepatitis B and cancer: A practical guide for the oncologist. Crit. Rev. Oncol. Hematol, 2016; 98: 137–146.
Bratanata J, Gani RA, Karjadi TH. Proporsi infeksi virus hepatitis B tersamar pada pasien yang terinfeksi human immunodeficiency virus. J. Penyakit Dalam Indones, 2017; 2: 126.
Triani E. Infeksi hepatitis B tersamar (occult hepatitis B infection) dan kanker hati primer. J. Kedokt, 2016; 5: 45–47.
Liu P, Xie SH, Hu S, Cheng X, Gao T, et al. Age-specific sex difference in the incidence of hepatocellular carcinoma in the United States. Oncotarget, 2017; 8(40): 68131–68137.
Sayaf K, Gabbia D, Russo FP, De Martin, S. The role of sex in acute and chronic liver damage. International Journal of Molecular Sciences, 2022; 23(18): 10654.
Pok Sharon, Barn VA, Wong HJ, Blackburn AC, Board P, et al. Testosterone regulation of cyclin E kinase: A key factor in determining gender differences in hepatocarcinogenesis. Journal of Gastroenterology and Hepatology (Australia), 2016; 31(6): 1210–1219.
Chayanupatkul M, Omino R, Mittal S, Kramer JR, Richardson P, et al. Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection. Journal of Hepatology, 2017; 66(2): 355-362.
Maulidia VNR, Wardhani P, Setyoboedi B. AST, ALT and albumin level in chronic hepatitis B patients with and without complications of cirrhosis and hepatocellular carcinoma. Indonesian Journal of Clinical Pathology and Medical Laboratory, 2020; 26(3): 344–349.
Downloads
Submitted
Accepted
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
